Literature DB >> 7905390

In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid.

K Kassahun1, F Abbott.   

Abstract

The terminal olefin metabolite of valproic acid (VPA), 4-ene VPA, is an analog of the experimental hepatotoxin 4-pentenoic acid and is believed to play a role in the hepatotoxicity of VPA. The formation of glutathione and N-acetylcysteine conjugates of the putative electrophilic metabolites of 4-ene VPA and 4-pentenoic acid was studied in vivo in the rat. Animals were treated intraperitoneally with the sodium salts of VPA, 4-ene VPA, (E)-2,4-diene VPA, 4-pentenoic or (E)-2,4-pentadienoic acids, and methylated bile and urine extracts were analyzed by LC/MS/MS and GC/MS techniques. The alpha,beta-unsaturated reactive metabolite of 4-pentenoic acid, 3-oxo-4-pentenoic acid, was isolated and identified as its thiol conjugates. In contrast, 3-oxo-4-ene VPA or its thiol conjugates could not be demonstrated as metabolites even though synthetic standards were available to facilitate their detection. Isolation of the thiol conjugates of 3-oxo-4-pentenoic acid provides the first direct spectroscopic evidence for the in vivo formation of the metabolite of 4-pentenoic acid considered responsible for the irreversible inhibition of fatty acid metabolism. The biliary and urinary metabolite profiles of 4-ene VPA and 4-pentenoic acid revealed basic differences between the in vivo metabolism of these two unsaturated carboxylic acids.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7905390

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

Review 1.  Identifying genomic and developmental causes of adverse drug reactions in children.

Authors:  Mara L Becker; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-11       Impact factor: 2.533

Review 2.  Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bio-activation, and detoxification processes.

Authors:  Christopher A Reilly; Garold S Yost
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

3.  Comparison of LC-MS/MS vs chemiluminescent microparticle immunoassay in measuring the valproic acid concentration in plasma of epilepsy patients in a new perspective.

Authors:  Zhipeng Wang; Yunlei Yun; Xinfang Xie; Chunhua You; Haijun Miao; Feng Zhang; Shouhong Gao; Wansheng Chen
Journal:  J Clin Lab Anal       Date:  2017-02-15       Impact factor: 2.352

4.  The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acid.

Authors:  Christian Riebeling; Ralph Pirow; Klaus Becker; Roland Buesen; Daniel Eikel; Johanna Kaltenhäuser; Frauke Meyer; Heinz Nau; Birgitta Slawik; Anke Visan; Jutta Volland; Horst Spielmann; Andreas Luch; Andrea Seiler
Journal:  Toxicol Sci       Date:  2011-01-11       Impact factor: 4.849

5.  Valproic acid pathway: pharmacokinetics and pharmacodynamics.

Authors:  Yogita Ghodke-Puranik; Caroline F Thorn; Jatinder K Lamba; J Steven Leeder; Wen Song; Angela K Birnbaum; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-04       Impact factor: 2.089

Review 6.  Molecular pharmacology in a simple model system: implicating MAP kinase and phosphoinositide signalling in bipolar disorder.

Authors:  Marthe H R Ludtmann; Katrina Boeckeler; Robin S B Williams
Journal:  Semin Cell Dev Biol       Date:  2010-11-18       Impact factor: 7.727

7.  Potential of the zebrafish (Danio rerio) embryo test to discriminate between chemicals of similar molecular structure-a study with valproic acid and 14 of its analogues.

Authors:  Katharina Brotzmann; Sylvia E Escher; Paul Walker; Thomas Braunbeck
Journal:  Arch Toxicol       Date:  2022-08-03       Impact factor: 6.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.